Bruker Corporation reported $3.50B of revenue over the trailing twelve months, +1.6% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $3.50B (to Q2 2026). Net income: −$71M, trailing twelve months to Q2 2026. Free cash flow: $94M, trailing twelve months to Q2 2026. Operating margin: −1.2%, trailing twelve months to Q2 2026.

BRKRBruker Corporation

Healthcare

$58.83+78% 1Y

$58.83

$30.6852 weeks$64.74

BRKR as reported

Bruker Corporation reported $3.50B of revenue over the trailing twelve months, +1.6% on the year before. 11 reported series are charted on this page, each one as filed.

$3.50B

Revenue, trailing twelve months · to Q2 2026 · +1.6% against the twelve months before

Net income: −$71M
Net income · −189% year on year · trailing twelve months to Q2 2026
Free cash flow: $94M
Free cash flow · +90% year on year · trailing twelve months to Q2 2026
Operating margin: −1.2%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BRKR, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$3.50B	+1.6%	Q2 2026
Net income	−$71M	−189%	Q2 2026
EPS	−$0.70	−235%	Q2 2026
Gross margin	46%	n/a	Q2 2026
Operating margin	−1.2%	n/a	Q2 2026
Net margin	−2.2%	n/a	Q2 2026
ROE	−1.2%	n/a	Q2 2026
ROA	−0.46%	n/a	Q2 2026
ROIC	0.72%	n/a	Q2 2026
Free cash flow	$94M	+90%	Q2 2026
P/E	67.1	n/a	Q2 2025 · 4 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.